Dyspepsia (Indigestion) – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData’s clinical trial report provides an overview of the dyspepsia (indigestion) clinical trials scenario. This report provides top-line data relating to the clinical trials on dyspepsia (indigestion). The report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials (based on the number of ongoing trials). The report enhances the decision-making capabilities and helps to create effective counterstrategies to gain a competitive advantage.
The dyspepsia (indigestion) clinical trial report consists of 756 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, and Phase I stand at 49, 65, 103, and 128 respectively. Similarly, the trials with different status compile of Completed – 548, Ongoing – 75, Planned – 52, Suspended – 3, Terminated – 18, and withdrawn – 60. Out of 548 completed trials 276 trials have achieved endpoint.
What are the market dynamics of the global dyspepsia (indigestion) therapeutics clinical trials sector?
The number of dyspepsia (indigestion) clinical trials conducted globally has increased by 25% for the period 2016-2020. The average number of patients enrolled was highest in the year 2017. Out of the total clinical trials conducted, over 35% of trials have been sponsored by the company and more than 55% by institutions. As of November 2021, there were 75 clinical trials in progress and 548 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 81. This was due to the lack of efficacy, safety, and lack of accrual of subjects. Out of 548 completed trials, 323 trials have results and 276 (85%) of trials reached endpoints.
What are the top regions and countries in the global dyspepsia (indigestion) therapeutics clinical trials sector?
In total there were 756 clinical trials conducted on dyspepsia (indigestion), as of November 2021, of these 382 clinical trials were in Asia-Pacific. More than 50% of the clinical trials were conducted in Asia-Pacific. During the same period, Germany has the highest average patient enrollment of dyspepsia (indigestion) clinical trials.
Asia-Pacific: In the Asia-Pacific region, China has the highest number of dyspepsia (indigestion) clinical trials, as of November 2021, followed by India, Japan, South Korea, and Thailand.
Europe: Among the European countries, Russia has the highest number of dyspepsia (indigestion) clinical trials, as of November 2021, followed by Belgium, Germany, the Netherlands, and the UK.
North America: In the country-wise analysis, the US has the highest number of dyspepsia (indigestion) clinical trials, as of November 2021, followed by Canada, and Mexico.
The Middle East & Africa: Iran, South Africa, Egypt, Kuwait, and Saudi Arabia are the leading countries in the region based on dyspepsia (indigestion) clinical trials.
Central and South America: Brazil has the highest number of dyspepsia (indigestion) clinical trials in the region followed by Colombia, Peru, Argentina, and Chile.
G7 countries: Among the G7 (the US, the UK, Germany, France, Italy, Canada, and Japan) countries, Japan has the highest proportion of Dyspepsia (indigestion) to gastrointestinal clinical trials as of November 2021. In total there were 183 clinical trials conducted on dyspepsia (indigestion), as of November 2021 in G7 Countries, of these 63 clinical trials were in Japan. During the same period, there were 12 clinical trials in progress and 133 trials are completed. The trials that are terminated/suspended or withdrawn accounted for 16. This was due to the lack of efficacy, safety, and lack of accrual of subjects.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Indonesia has the highest proportion of Dyspepsia (indigestion) to gastrointestinal clinical trials as of November 2021. During the same period, in total there were 275 clinical trials conducted on Dyspepsia (Indigestion), as of November 2021 in E7 Countries, of these 145 clinical trials were in China. There were 31 clinical trials in progress and 170 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 44. As of November 2021, the majority of the trials were successfully completed.
Global dyspepsia (indigestion) therapeutics clinical trials sector, by regions
For more regional insights, download a free report sample
Which are the key companies in the global dyspepsia (indigestion) therapeutics clinical trials sector?
As of November 2021, Zeria Pharmaceutical Co Ltd sponsored the highest number of dyspepsia (indigestion) clinical trials, followed by Dr. Reddy’s Laboratories Ltd, and Novartis AG. Other major companies in the sector are Astellas Pharma Inc, Takeda Pharmaceutical Co Ltd, Bayer AG, AstraZeneca Plc, Eisai Co Ltd, Daewoong Co Ltd, and Dong-A Socio Group.
Global dyspepsia (indigestion) therapeutics clinical trials sector, by key companies
To know more about key companies, download a free report sample
Market report scope
Key countries | China, Iran, India, Japan, the US, South Korea, Russia, Belgium, Thailand, and Germany |
Key companies | Zeria Pharmaceutical Co Ltd, Dr. Reddy’s Laboratories Ltd, Novartis AG, Astellas Pharma Inc, Takeda Pharmaceutical Co Ltd, Bayer AG, AstraZeneca Plc, Eisai Co Ltd, Daewoong Co Ltd, and Dong-A Socio Group |
Scope
- The report provides a snapshot of the global clinical trials landscape.
- Report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment.
- The report provides enrollment trends for the past five years.
- Report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrolment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level.
Dr. Reddy's Laboratories Ltd
Novartis AG
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
Takeda Pharmaceutical Co Ltd
Eisai Co Ltd
Daewoong Co Ltd
Dong-A Socio Group
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key countries in the global dyspepsia (indigestion) therapeutics clinical trials sector?
The key countries in the global dyspepsia (indigestion) therapeutics clinical trials sector are China, Iran, India, Japan, the US, South Korea, Russia, Belgium, Thailand, and Germany.
-
Which are the key companies in the global dyspepsia (indigestion) therapeutics clinical trials sector?
The key companies in the global dyspepsia (indigestion) therapeutics clinical trials sector are Zeria Pharmaceutical Co Ltd, Dr. Reddy’s Laboratories Ltd, Novartis AG, Astellas Pharma Inc, Takeda Pharmaceutical Co Ltd, Bayer AG, AstraZeneca Plc, Eisai Co Ltd, Daewoong Co Ltd, and Dong-A Socio Group.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.